首页> 美国卫生研究院文献>Genetic Testing and Molecular Biomarkers >Prevalence of the NKG2D Thr72Ala Polymorphism in Patients with Cervical Carcinoma
【2h】

Prevalence of the NKG2D Thr72Ala Polymorphism in Patients with Cervical Carcinoma

机译:宫颈癌患者NKG2D Thr72Ala多态性的患病率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: The natural killer group 2, member D (NKG2D) receptor is mainly situated on the surface of NK and CD8+ αβ T cells that are involved in the defense against viral agents and in cancer immunosurveillance. The G>A transition (Thr72Ala) (rs2255336) located in the NKG2D region encoding the transmembrane part of this receptor has been associated with decreased functionality of NK and T cells. Methods: Using polymerase chain reaction–restriction fragment length polymorphisms, we examined the NKG2D Thr72Ala polymorphism in patients with cervical cancer (n=353) and controls (n=366) in a Polish population. Results: We observed an increased frequency of Thr/Thr or/and Thr/Ala genotypes in controls compared with all patients with cervical cancer; however, these differences were not significant. We found a significantly increased frequency of the NKG2D 72Thr allele in controls than in all patients (odds ratio [OR]=0.7410 [95% confidence intervals (CI)=0.5683–0.9662, p=0.0265]). Moreover, stratification of patients based on cancer stage showed a significant increase in the Thr/Thr genotype frequency (OR=0.3086 [95% CI=0.09097–1.047, p=0.0461]), as well as in the Thr/Thr and Thr/Ala genotype frequency (OR=0.4504 [95% CI=0.2891–0.7018, p=0.0003]), in controls compared with patients with cervical cancer in stages III and IV. The frequency of the NKG2D 72Thr allele was also significantly increased in controls as compared with patients in stage III and IV cancer (OR=0.4699 [95% CI=0.3170–0.6967, p=0.0001]). Conclusion: Our studies may suggest that the women with cervical cancer bearing the NKG2D 72Thr gene variant might be protected against progression to advanced stages of this cancer.
机译:背景:自然杀手2组D成员(NKG2D)受体主要位于NK和CD8 + αβT细胞的表面,这些细胞参与抗病毒剂的防御和癌症免疫监视。位于NKG2D区域的G> A过渡区(Thr72Ala)(rs2255336)编码该受体的跨膜部分,与NK和T细胞的功能降低有关。方法:使用聚合酶链反应-限制性片段长度多态性,我们检查了波兰人群中宫颈癌(n = 353)和对照(n = 366)患者的NKG2D Thr72Ala多态性。结果:与所有宫颈癌患者相比,我们在对照组中观察到Thr / Thr或/和Thr / Ala基因型的频率增加。但是,这些差异并不明显。我们发现对照组中NKG2D 72Thr等位基因的频率显着高于所有患者(赔率[OR] = 0.7410 [95%置信区间(CI)= 0.5683-0.9662,p = 0.0265])。此外,根据癌症分期对患者进行分层显示,Thr / Thr基因型频率显着增加(OR = 0.3086 [95%CI = 0.09097-1.047,p = 0.0461]),以及Thr / Thr和Thr /与III期和IV期宫颈癌患者相比,对照组的Ala基因型频率(OR = 0.4504 [95%CI = 0.2891–0.7018,p = 0.0003])。与处于III期和IV期癌症的患者相比,对照组中NKG2D 72Thr等位基因的频率也显着增加(OR = 0.4699 [95%CI = 0.3170-0.6967,p = 0.0001])。结论:我们的研究可能提示携带NKG2D 72Thr基因变异的宫颈癌女性可以预防其发展为晚期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号